Endra Life Sciences Inc Financials

NDRA

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Endra Life Sciences Inc (NDRA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

2/9

Endra Life Sciences Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.64x

For every $1 of reported earnings, Endra Life Sciences Inc generates $0.64 in operating cash flow (-$7.4M OCF vs -$11.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Revenue

N/A

EBITDA

-$10.8M

YoY-3.6%

Endra Life Sciences Inc's EBITDA was -$10.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 3.6% from the prior year.

Free Cash Flow

-$7.4M

YoY+22.6%

Endra Life Sciences Inc generated -$7.4M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 22.6% from the prior year.

Net Income

-$11.5M

YoY-14.4%

Endra Life Sciences Inc reported -$11.5M in net income in fiscal year 2024. This represents a decrease of 14.4% from the prior year.

EPS (Diluted)

$-56.94

Endra Life Sciences Inc earned $-56.94 per diluted share (EPS) in fiscal year 2024. This represents an increase of 97.9% from the prior year.

Cash & Debt

$3.2M

YoY+14.0%

5Y CAGR-12.2%

Endra Life Sciences Inc held $3.2M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

536,908

Endra Life Sciences Inc had 536,908 shares outstanding in fiscal year 2024. This represents an increase of 8943.4% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$3.2M

YoY-36.2%

5Y CAGR-13.5%

Endra Life Sciences Inc invested $3.2M in research and development in fiscal year 2024. This represents a decrease of 36.2% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$16K

YoY-52.8%

5Y CAGR-18.2%

Endra Life Sciences Inc invested $16K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 52.8% from the prior year.

NDRA Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	N/A	N/A	N/A	$0	$0
Cost of Revenue	N/A	N/A	N/A	N/A	$0	$0
Gross Profit	N/A	N/A	N/A	N/A	$0	$0
R&D Expenses	$3.2M-36.2%	$5.0M-23.7%	$6.6M+19.5%	$5.5M-7.4%	$5.9M-10.0%	$6.6M
SG&A Expenses	$7.1M+50.2%	$4.7M-9.2%	$5.2M+4.7%	$4.9M-1.2%	$5.0M+29.7%	$3.9M
Operating Income	-$10.8M-2.8%	-$10.5M+20.0%	-$13.2M-14.4%	-$11.5M0.0%	-$11.5M-6.1%	-$10.8M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0	$0	$0	$0	$0	$0
Net Income	-$11.5M-14.4%	-$10.1M+23.7%	-$13.2M-17.3%	-$11.2M+4.2%	-$11.7M+11.9%	-$13.3M
EPS (Diluted)	$-56.94	$-2766.85	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$432K+13.4%	$381K-27.9%	$529K-33.5%	$794K+10.9%	$716K-31.2%	$1.0M	N/A	$1.6M
SG&A Expenses	$893K+4.9%	$851K-2.3%	$872K+38.0%	$631K-53.3%	$1.4M-9.9%	$1.5M	N/A	$1.3M
Operating Income	-$1.4M-5.4%	-$1.3M+11.4%	-$1.5M+2.6%	-$1.5M+32.4%	-$2.2M+19.8%	-$2.8M	N/A	-$3.1M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	$0	$0	$0	$0	$0	N/A	$0
Net Income	-$1.6M-30.2%	-$1.2M-18.3%	-$1.0M+56.0%	-$2.4M-5.6%	-$2.2M+19.7%	-$2.8M	N/A	-$3.1M
EPS (Diluted)	$-2.10	N/A	N/A	$-9.54	N/A	N/A	N/A	N/A

NDRA Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$4.5M-34.1%	$6.8M-27.2%	$9.3M-28.0%	$12.9M+46.9%	$8.8M+22.1%	$7.2M
Current Assets	$3.4M+13.2%	$3.0M-43.6%	$5.4M-55.5%	$12.1M+47.4%	$8.2M+25.6%	$6.5M
Cash & Equivalents	$3.2M+14.0%	$2.8M-42.0%	$4.9M-48.3%	$9.5M+30.9%	$7.2M+17.1%	$6.2M
Inventory	$0-100.0%	$2.6M-0.8%	$2.6M+105.9%	$1.3M+117.9%	$590K+419.8%	$113K
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.9M+72.8%	$1.1M-47.1%	$2.1M-1.0%	$2.1M+31.0%	$1.6M-33.9%	$2.4M
Current Liabilities	$605K-33.0%	$903K-47.0%	$1.7M+10.4%	$1.5M+56.5%	$987K-52.4%	$2.1M
Long-Term Debt	$0	$0	$0-100.0%	$547K	N/A	N/A
Total Equity	$2.6M-54.8%	$5.7M-21.5%	$7.2M-33.2%	$10.8M+50.4%	$7.2M+50.6%	$4.8M
Retained Earnings	-$103.4M-12.5%	-$91.9M-12.3%	-$81.9M-19.2%	-$68.7M-19.8%	-$57.3M-26.8%	-$45.2M

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Total Assets	$2.0M-30.0%	$2.8M-11.4%	$3.2M-28.8%	$4.5M-57.4%	$10.4M+106.3%	$5.1M-25.1%	$6.8M-11.2%	$7.6M
Current Assets	$1.0M-43.4%	$1.9M-15.0%	$2.2M-36.5%	$3.4M-48.9%	$6.7M+428.4%	$1.3M-58.1%	$3.0M-52.6%	$6.4M
Cash & Equivalents	$794K-56.1%	$1.8M-12.4%	$2.1M-36.1%	$3.2M-49.5%	$6.4M+464.1%	$1.1M-60.0%	$2.8M-15.0%	$3.3M
Inventory	$0	$0	$0	$0-100.0%	$2.7M0.0%	$2.7M+3.4%	$2.6M-4.9%	$2.8M
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.8M+34.3%	$1.3M-5.9%	$1.4M-25.1%	$1.9M+30.6%	$1.4M+6.3%	$1.4M+24.4%	$1.1M-54.5%	$2.4M
Current Liabilities	$800K+38.8%	$577K+1.9%	$566K-6.5%	$605K-55.2%	$1.4M+11.0%	$1.2M+34.7%	$903K-58.4%	$2.2M
Long-Term Debt	N/A	N/A	N/A	$0	N/A	$0	$0	N/A
Total Equity	$171K-88.4%	$1.5M-16.0%	$1.8M-31.5%	$2.6M-71.5%	$9.0M+143.2%	$3.7M-34.6%	$5.7M+8.9%	$5.2M
Retained Earnings	-$107.3M-1.5%	-$105.7M-1.2%	-$104.5M-1.0%	-$103.4M-6.7%	-$96.9M-2.4%	-$94.7M-3.0%	-$91.9M-1.6%	-$90.5M

NDRA Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$7.4M+22.5%	-$9.5M+25.2%	-$12.8M-14.8%	-$11.1M-3.5%	-$10.7M-25.1%	-$8.6M
Capital Expenditures	$16K-52.8%	$34K-83.3%	$203K+350.2%	$45K-40.3%	$75K+72.8%	$44K
Free Cash Flow	-$7.4M+22.6%	-$9.6M+26.1%	-$13.0M-16.2%	-$11.2M-3.2%	-$10.8M-25.4%	-$8.6M
Investing Cash Flow	-$13K+48.2%	-$25K+87.8%	-$203K-350.2%	-$45K+40.3%	-$75K-72.8%	-$44K
Financing Cash Flow	$7.8M+3.9%	$7.5M-10.5%	$8.4M-37.3%	$13.4M+12.9%	$11.9M+42.5%	$8.3M
Dividends Paid	N/A	N/A	$0-100.0%	$121K-69.4%	$396K-90.6%	$4.2M
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Operating Cash Flow	-$1.2M-4.5%	-$1.1M+13.9%	-$1.3M+14.7%	-$1.5M+27.2%	-$2.1M+2.8%	-$2.1M+1.4%	-$2.2M+16.3%	-$2.6M
Capital Expenditures	$0	$0-100.0%	$17K	$0+100.0%	-$11K-140.7%	$27K+292.2%	$7K	$0
Free Cash Flow	-$1.2M-4.5%	-$1.1M+15.0%	-$1.3M+13.5%	-$1.5M+27.6%	-$2.1M+3.5%	-$2.2M+0.5%	-$2.2M+16.1%	-$2.6M
Investing Cash Flow	$0	$0+100.0%	-$17K	$0-100.0%	$11K+146.2%	-$24K-1144.1%	$2K	$0
Financing Cash Flow	$149K-82.6%	$857K+488.1%	$146K	$0-100.0%	$7.3M+1465.0%	$469K-72.0%	$1.7M+50.1%	$1.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

NDRA Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-258.5%-109.5pp	-149.0%-6.8pp	-142.1%-54.9pp	-87.2%+46.5pp	-133.8%+51.6pp	-185.4%
Current Ratio	5.67+2.3	3.36+0.2	3.16-4.7	7.83-0.5	8.32+5.2	3.15
Debt-to-Equity	0.000.0	0.000.0	0.00-0.1	0.05-0.2	0.22-0.3	0.51
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-81.3%-37.6pp	-43.7%-11.0pp	-32.7%-4.6pp	-28.1%-6.7pp	-21.3%+33.5pp	-54.9%	N/A	-40.8%
Current Ratio	1.31-1.9	3.21-0.6	3.85-1.8	5.67+0.7	4.97+3.9	1.04-2.3	3.36+0.4	2.95
Debt-to-Equity	10.46+9.6	0.91+0.1	0.81+0.8	0.00-0.2	0.16+0.2	0.000.0	0.00-0.5	0.46
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Check Cap CHEK

$9.4M

Applied Dna Scie APDN

$7.3M

bioAffinity Tech BIAF

$4.7M

Mainz Biomed NV MYNZ

$7.2M

XWELL Inc XWEL

$2.5M

Frequently Asked Questions

Is Endra Life Sciences Inc profitable?

No, Endra Life Sciences Inc (NDRA) reported a net income of -$11.5M in fiscal year 2024.

What is Endra Life Sciences Inc's earnings per share (EPS)?

Endra Life Sciences Inc (NDRA) reported diluted earnings per share of $-56.94 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Endra Life Sciences Inc's EBITDA?

Endra Life Sciences Inc (NDRA) had EBITDA of -$10.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Endra Life Sciences Inc have?

As of fiscal year 2024, Endra Life Sciences Inc (NDRA) had $3.2M in cash and equivalents against $0 in long-term debt.

What is Endra Life Sciences Inc's free cash flow?

Endra Life Sciences Inc (NDRA) generated -$7.4M in free cash flow during fiscal year 2024. This represents a 22.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Endra Life Sciences Inc's operating cash flow?

Endra Life Sciences Inc (NDRA) generated -$7.4M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Endra Life Sciences Inc's total assets?

Endra Life Sciences Inc (NDRA) had $4.5M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Endra Life Sciences Inc's capital expenditures?

Endra Life Sciences Inc (NDRA) invested $16K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Endra Life Sciences Inc spend on research and development?

Endra Life Sciences Inc (NDRA) invested $3.2M in research and development during fiscal year 2024.

How many shares does Endra Life Sciences Inc have outstanding?

Endra Life Sciences Inc (NDRA) had 536,908 shares outstanding as of fiscal year 2024.

What is Endra Life Sciences Inc's current ratio?

Endra Life Sciences Inc (NDRA) had a current ratio of 5.67 as of fiscal year 2024, which is generally considered healthy.

What is Endra Life Sciences Inc's debt-to-equity ratio?

Endra Life Sciences Inc (NDRA) had a debt-to-equity ratio of 0.00 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Endra Life Sciences Inc's return on assets (ROA)?

Endra Life Sciences Inc (NDRA) had a return on assets of -258.5% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Endra Life Sciences Inc's cash runway?

Based on fiscal year 2024 data, Endra Life Sciences Inc (NDRA) had $3.2M in cash against an annual operating cash burn of $7.4M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Endra Life Sciences Inc's Piotroski F-Score?

Endra Life Sciences Inc (NDRA) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Endra Life Sciences Inc's earnings high quality?

Endra Life Sciences Inc (NDRA) has an earnings quality ratio of 0.64x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.